Statistics for Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer
Total visits
views | |
---|---|
Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer | 176 |
Total visits per month
views | |
---|---|
October 2024 | 0 |
November 2024 | 0 |
December 2024 | 0 |
January 2025 | 0 |
February 2025 | 0 |
March 2025 | 0 |
April 2025 | 0 |
File Visits
views | |
---|---|
41467_2018_Article_7264.pdf | 156 |
java.util.UUID:b9ce7e27-68e1-4c7e-9125-b0ca148abe79 | 38 |
java.util.UUID:c038f78c-7e60-4b83-9443-c6b7e3784b6e | 16 |
java.util.UUID:1144bcfc-e95f-4287-abec-63a98854e3cb | 5 |
Top country views
views | |
---|---|
United States | 133 |
Germany | 7 |
Ukraine | 5 |
Canada | 3 |
United Kingdom | 3 |
China | 1 |
Greece | 1 |
Iran | 1 |
Italy | 1 |
Malaysia | 1 |
Russia | 1 |
Sweden | 1 |
Vietnam | 1 |
Top city views
views | |
---|---|
Wilmington | 46 |
Fairfield | 18 |
Houston | 14 |
San Francisco | 7 |
Jacksonville | 6 |
Kiev | 5 |
Kiez | 5 |
Ann Arbor | 4 |
Baltimore | 4 |
Cambridge | 4 |
Toronto | 3 |
Gunzenhausen | 2 |
Athens | 1 |
Beijing | 1 |
Bloomington | 1 |
Bolzano | 1 |
Brooklyn | 1 |
Chevy Chase | 1 |
Hanoi | 1 |
Monmouth Junction | 1 |
Scottsdale | 1 |
Seremban | 1 |
Stockholm | 1 |
Tehran | 1 |
Zheleznogorsk | 1 |